门静脉血栓及肝动脉-门静脉瘘诊治再认识*

doi:10.3969/j.issn.1672-5069.2023.02.003

Abstract

Shi Haitao, Lu Xiaolan. Portal vein thrombosis and hepatic arterio-portal fistula: a re-conceptualization of the diagnosis and treatment[J]. Journal of Practical Hepatology, 2023, 26(2): 160-163.

[1] Catherine NB, Arya R. Virchow and his triad: a question of attribution. Bri J Hematol, 2008, 143(2): 180-190.
[2] Anton A, Camprecios G, Perez-Campuzano V, et al. Thepathophysiology of portal vein thrombosis in cirrhosis: getting deeper into Virchow's triad. J Clin Med, 2022, 11(3): 800.
[3] Odriozola A, Puente Á, Cuadrado A, et al. Portal vein thrombosis in the setting of cirrhosis: A comprehensive review. J Clin Med, 2022, 11(21): 6435.
[4] Ju C, Li X, Gadani S, et al. Portal vein thrombosis: diagnosis and endovascular management. Rofo, 2022, 194(2): 169-180.
[5] Carnevale R, Raparelli V, Nocella C, et al. Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells: implications for hypercoagulability in cirrhosis. J Hepatol, 2017, 67(5): 950-956.
[6] Kheyrandish S, Rastgar A, Arab-Zozani M, et al. Portal vein thrombosis might develop by COVID-19 infection or vaccination: a systematic review of case-report studies. Front Med (Lausanne), 2021, 8: 794599.
[7] Ogren M, Bergqvist D, Björck M, et al. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23, 796 consecutive autopsies. World J Gastroenterol, 2006, 12(13): 2115-2119.
[8] 中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年, 上海). 临床肝胆病杂志, 2020, 36(12): 2667-2674.
[9] Envelope RDFP, Bosch J, Garcia-Tsao G, e al. Baveno VII-renewing consensus in portal hypertension. J Hepatol, 2022, 76(4): 959-974.
[10] Dai J, Qi X, Li H, et al. Role ofD-dimer in the development of portal vein thrombosis in liver cirrhosis: a meta-analysis. Saudi J Gastroenterol, 2015, 21(3): 165-174.
[11] 张冬磊, 郝建宇, 杨宁. D-二聚体对肝硬化门静脉血栓形成的预测价值. 中华消化杂志, 2008, 28(10): 708-709.
[12] Wei Y, Chen X, Shen H, et al. P-selectin level at first and third day after portal hypertensive splenectomy for early prediction of portal vein thrombosis in patients with cirrhosis. Clin Appl Thromb Hemost, 2018, 24(suppl 9): 76s-83s.
[13] Buliarca A, Horhat A, Mocan T, et al. Viscoelastic tests in liver disease: where do we stand now? World J Gastroenterol, 2021, 27(23): 3290-3302.
[14] Fainchtein K, Tera Y, Kearn N, et al. Hypercoagulability and thrombosis risk in prostate cancer: the role of thromboelastography. Semin Thromb Hemost, 2022[ahead of print].
[15] Tarantino L, Ambrosino P, Minno M. Contrast-enhanced ultrasound in differentiating malignant from benign portal vein thrombosis in hepatocellular carcinoma. World J Gastroenterol, 2015, 21(32): 9457-9460.
[16] Margini C, Berzigotti A. Portal vein thrombosis: The role of imaging in the clinical setting. Dig Liver Dis, 2017, 49(2): 113-120.
[17] Sofia C, Cattafi A, Silipigni S, et al. Portal vein thrombosis in patients with chronic liver diseases: from conventional to quantitative imaging. Eur J Radiol, 2021, 142: 109859.
[18] Lorenzo L, Pastori D, Farcomeni A, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology, 2017, 153(2): 480-487.
[19] Chun HS, Choe AR, Lee M, et al. Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis. Clin Mol Hepatol, 2021, 27(4): 535-552.
[20] Liu K, Li WD, Du XL, et al. Comparison of systemic thrombolysis versus indirect thrombolysis via the superior mesenteric artery in patients with acute portal vein thrombosis. Ann Vasc Surg, 2017, 39: 264-269.
[21] Rodrigues SG, Sixt S, Abraldes JG, et al. Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Aliment Pharmacol Ther, 2019, 49(1): 20-30.
[22] Hollingshead M, Burke CT, Mauro MA, et al. Transcatheter thrombolytic therapy for acute mesenteric and portal vein. J Vasc Interv Radiol, 2005, 16(5): 651-661.
[23] Heaton ND, Davenport M, Karani J, et al. Congenital hepatoportal arteriovenous fistula. Surgery, 1995, 117(2): 170-174.
[24] Wu HY, Zhao W, Zhang JB, et al. Clinical characteristics of hepaticarterioportal shunts associated with hepatocellular carcinoma. BMC Gastroenterol, 2018, 18(1): 174.
[25] Guzman EA, McCahill LE, Rogers FB. Arterioportal fistulas: introduction of a novel classification with therapeutic implications. J Gastrointest Surg, 2006, 10(4): 543-550..
[26] Okuda K, Musha H, Yamasaki T, et al. Angiographic demonstration of intrahepatic arterio-portal anastomoses in hepatocellular carcinoma. Radiology, 1977, 122(1): 53-58.
[27] Zhang DY, Weng SQ, Dong L, et al. Portal hypertension induced by congenital hepatic arterioportal fistula: report of four clinical cases and review of the literature. World J Gastroenterol, 2015, 21(7): 2229-2235.
[28] Nakayama S. Intrahepatic arterioportal fistula. Intern Med, 2013, 52(20): 2371.
[29] Teplisky D, Tincani E, Lipsich J, et al. Congenital arterioportal fistulas: radiological treatment and color Doppler US follow-up. Pediatr Radiol, 2012, 42(11): 1326-1332.
[30] 陈志辉, 陈方红, 纪建松, 等. 超声造影对肝癌射频消融后继发性肝动脉-门静脉瘘的诊断价值. 医学影像学杂志, 2019, 29(2): 252-256.
[31] Sharpley J, Thode H, Sestina L, et al. Distal abdominal aortic thrombosis diagnosed by three-dimensional contrast-enhanced magnetic resonance angiography. Vet Radiol Ultrasound, 2009, 50(4): 370-375.
[32] Dumortier J, Pilleul F, Adham M, et al. Severe portal hypertension secondary to arterio-portal fistula: salvage surgical treatment. Liver Int, 2007, 27(6): 865-868.
[33] Saad WE, Davies MG, Rubens DJ, et al. Endoluminal management of arterioportal fistulae in liver transplant recipients: a single-center experience. Vasc Endovascular Surg, 2006, 40(6): 451-459.

Portal vein thrombosis and hepatic arterio-portal fistula: a re-conceptualization of the diagnosis and treatment

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Yan, Zhou Jing, Han Jun. Clinicopathological features of patients with autoimmune hepatitis and drug-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(2): 218-221.
[2]	Xu Jing, Liu Kun, Ma Zhufang. Clinical efficacy of magnesium isoglycyrrhizinate in preventing and treating liver and kidney injuries in patients with advanced gastric cancer undergoing chemotherapy [J]. Journal of Practical Hepatology, 2023, 26(2): 234-237.
[3]	Chinese Society of Hepatology, Chinese Society of Gastroenterology, and Chinese Society of Digestive Endoscopology of Chinese Medical Association. Guidelines on the Management of EVB in Cirrhotic Portal Hypertension [J]. Journal of Practical Hepatology, 2023, 26(2): 0-S4.
[4]	Huang Xiaoquan, Chen Shiyao. Standardization treatment of patients with portal hypertension and gastroesophageal variceal bleeding [J]. Journal of Practical Hepatology, 2023, 26(1): 1-3.
[5]	Lai Ruimin, Zhu Yuejiu. Portal hypertension: indication of transjugular intrahepatic portosystemic shunt and the prevention of related complications [J]. Journal of Practical Hepatology, 2023, 26(1): 4-7.
[6]	Lin Shiwen, Han Feng, Wei Yu, et al. Changes of serum miR-21 and miR-124a levels in patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(1): 43-46.
[7]	Xu Qing, Yang Jian, Zong Jinjuan. Imaging and histopathological features in patients with idiopathic non-cirrhotic portal hypertension [J]. Journal of Practical Hepatology, 2023, 26(1): 91-94.
[8]	Zhang Wei, Hou Wei, Liu Hui, et al. Recurrence three years after liver transplantation of patients with idiopathic portal hypertension: A case report and literature review [J]. Journal of Practical Hepatology, 2023, 26(1): 136-139.
[9]	Zhao Zide, Wu Lingjie, Zhang Haisheng, et al.. Could the supplement of human blood albumin product reduce the incidence of drug-induced liver injury in patients with pulmonary tuberculosis and hypoproteinemia? [J]. Journal of Practical Hepatology, 2022, 25(6): 792-795.
[10]	Zhu Haiyan, Fan Xiaotang. Nomogram model in predicting portal venous thrombosis in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 848-852.
[11]	Cui Po, Dong Shiming, Nan Yuemin. Prognosis of COVID-19 patients with underlying chronic liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 905-908.
[12]	Wang Qian, Li Wenli, Wang Bing, et al.. Clinical characteristics of patients with Dengue fever: A report of 70 cases [J]. Journal of Practical Hepatology, 2022, 25(5): 645-648.
[13]	Liu Yan, Shen Yu,Zhang Qian. Characteristics and clinical outcomes of 60 patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2022, 25(5): 649-652.
[14]	Li Ting,Mao Xiaorong, Zhang Xuemei, et al.. Comparison of incidence of portal vein thrombosis in cirrhotics with hypersplenism after undergoing splenectomy or TIPS [J]. Journal of Practical Hepatology, 2022, 25(5): 685-688.
[15]	Yang Jing, Cheng Yanli. Idiopathic non-cirrhotic portal hypertension: one case report and literature review [J]. Journal of Practical Hepatology, 2022, 25(5): 750-752.